- Home
- AAT vs SLNO Comparison
AAT vs SLNO Comparison
Compare AAT & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAT
- SLNO
- Stock Information
- Founded
- AAT 1967
- SLNO 1999
- Country
- AAT United States
- SLNO United States
- Employees
- AAT N/A
- SLNO N/A
- Industry
- AAT Real Estate Investment Trusts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AAT Real Estate
- SLNO Health Care
- Exchange
- AAT Nasdaq
- SLNO Nasdaq
- Market Cap
- AAT 1.3B
- SLNO 3.8B
- IPO Year
- AAT 2011
- SLNO 2014
- Fundamental
- Price
- AAT $20.60
- SLNO $50.98
- Analyst Decision
- AAT Hold
- SLNO Strong Buy
- Analyst Count
- AAT 2
- SLNO 10
- Target Price
- AAT $20.50
- SLNO $112.50
- AVG Volume (30 Days)
- AAT 304.2K
- SLNO 1.8M
- Earning Date
- AAT 10-28-2025
- SLNO 11-05-2025
- Dividend Yield
- AAT 6.55%
- SLNO N/A
- EPS Growth
- AAT 37.34
- SLNO N/A
- EPS
- AAT 1.22
- SLNO N/A
- Revenue
- AAT $448,315,000.00
- SLNO $32,656,999.00
- Revenue This Year
- AAT N/A
- SLNO N/A
- Revenue Next Year
- AAT $2.42
- SLNO $181.85
- P/E Ratio
- AAT $17.05
- SLNO N/A
- Revenue Growth
- AAT 1.71
- SLNO N/A
- 52 Week Low
- AAT $16.69
- SLNO $41.50
- 52 Week High
- AAT $29.15
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- AAT 53.32
- SLNO 25.29
- Support Level
- AAT $20.45
- SLNO $48.91
- Resistance Level
- AAT $20.93
- SLNO $72.99
- Average True Range (ATR)
- AAT 0.40
- SLNO 4.25
- MACD
- AAT -0.02
- SLNO -1.53
- Stochastic Oscillator
- AAT 58.02
- SLNO 8.62
About AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.